VRSK vs RPRX Comparison

Verisk is a leading data, analytics, and technology provider for property-casualty insurers. Verisk traces its history to Insurance Services Office, a nonprofit advisory organization founded in 1971 by US P&C insurers. ISO was formed as an association of insurance companies to assist with a variety of insurance use cases, such as reporting to regulators, defining policies, and determining independent premium rates. As the firm expanded its use cases, it became a for-profit company, renamed Verisk, and went public in 2009. Verisk's single segment (insurance) provides underwriting solutions, including forms, rules, loss costs, and catastrophe modeling. For claims, Verisk's solutions include property repair estimates and antifraud tools. About 83% of Verisk's revenue is US-based.

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.